cethromycin at the October 25-28 ICAAC/IDSA conference in
* Under the DTRA contract, expand advanced studies of cethromycin as a
broad spectrum medical countermeasure;
* Continue preparing for commercial launch of cethromycin through
manufacturing, market research, medical education, and pricing
* Dose first patient in ALS-357 PhaseI/II melanoma trial.
Financial Guidance for the Third Quarter of 2008
Advanced Life Sciences expects its third quarter 2008 cash requirements to fall in the range of $3.4 million and $3.7 million, leaving a cash balance of $5.4 million to $5.7 million as of September 30, 2008. Management believes that this cash balance will be sufficient to allow the Company to progress to the period in which it submits the NDA for cethromycin in the CAP indication to the FDA. To fund ongoing operations including the payment of any milestone payment due to Abbott Laboratories in connection with the submission of the cethromycin NDA, the Company intends to raise additional capital in 2008 through a commercial partnership and/or the sale of equity, if available at terms acceptable to us, which cannot be assured.
Conference Call Details
Advanced Life Sciences will host a conference call and live webcast at 10:00 a.m. Eastern Time on Thursday, August 14, 2008 to discuss the company's second quarter financial results.
The conference call will be webcast simultaneously over the Internet.
Please visit the Investor Relations section of the Advanced Life Sciences
corporate website http://www.advancedlifesciences.com. Alternatively,
callers may participate in the conference call by dialing 888-713-4218
(domestic) or 617-213-4870 (international). The passcode for the conference
|SOURCE Advanced Life Sciences Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved